Skip to content

Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy of the peptide on reducing body fat

Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy of the peptide on reducing body fat - Clinical study to evaluate the efficacy of the peptide on reducing body fat

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053658
Enrollment
100
Registered
2024-02-25
Start date
2024-02-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Sponsors

Yamaguchi Health Lab
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subjects aged more than 20 years, less than 65 years 2) Subjects with a BMI between 23 and 30

Exclusion criteria

Exclusion criteria: 1) Subjects who have serious disease or who have history of serious disease 2) Subjects who regularly undertake medications that affect obesity, hyperlipidemia or lipid metabolism 3) Subjects who cannot stop taking health foods or supplements that affect obesity, hyperlipidemia or lipid metabolism 4) Heavy smokers (more than 21 cigarettes/day) 5) Subjects who have excessive alcoholic drinks (more than 60 g/day of alcohol) 6) Subjects with serious medication allergy or food allergy 7) Subject who is pregnant or under lactation, or who is expected to be pregnant during the study 8) Subjects who are currently participating, or intend to participate during this study period, in other trials involving the testing of other foods or the use of drugs or the application of cosmetics and drugs 9) Subjects who are considered to be inappropriate for this study by the principal investigator or the examination doctor

Design outcomes

Primary

MeasureTime frame
Body fat

Secondary

MeasureTime frame
Body weight, BMI, Waist circumference

Countries

Japan

Contacts

Public ContactHisao Nakatani

Yamaguchi Health Lab General manager

info@yamaguchi-hl.com083-976-4095

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026